Detection of psychoactive drugs using19F MR spectroscopy
In vivo19F resonance spectroscopy measurements of trifluorinated neuroleptics (fluphenazine and trifluoperazine) and later trifluorinated antide-pressants (fluoxetine and fluvoxamine) began with animal experiments in 1983. Using rats which have been treated with high oral doses of fluphenazine over a period of three weeks in the beginning of these experiments the measurement time was very long (up to 10 h). The application of better techniques using surface coils led to marked improvement of the signal noise ratio and measurement times in animal experiments could be reduced to minutes. These results encouraged us and other groups to perform experiments in humans to detect and try to estimate brain levels of trifluorinated neuroleptics and antide-pressants. The present data of several research groups demonstrate that19F MR spectroscopy has the potential of becoming a valuable tool for monitoring drug levels at the site of action. The extension of the animal studies to humans might facilitate a better treatment of schizophrenic and depressive patients.
KeywordsSchizophrenia depression 19F MR spectroscopy
Unable to display preview. Download preview PDF.
- Albert K, Bartels M, Kruppa G, Mann K, Schroth G, Tabarelli S, Zabel M (1984) Untersuchung fluorsubstituierter Psychopharmaka mittels NMR. In: Pfannenstiel P, Meves M (Hrsg) Die NMR Tomographie. Klinischer Einsatz und Wirtschaftlichkeit. G Thieme, Stuttgart S 34–36Google Scholar
- Bartels M, Günther U, Albert K, Mann K, Schuff N, Stuckstedte H (1991)19F Nuclear magnetic resonance spectroscopy of neuroleptics: the first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain. Biol Psychiatry 30: 656–662PubMedGoogle Scholar
- Buchsbaum MS (1987) Positron emission tomography in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, p 783Google Scholar
- Durst P, Schuff N, Crocq MA, Mokrani MC, Macher JP (1990) Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by19F nuclear magnetic resonance spectroscopy. Psychiatry Res Neuroimaging 35: 107–114Google Scholar
- Joergensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridge JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London Philadelphia, p 111–174Google Scholar
- Karson CN, Newton JEO, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA (1993) Human brain fluoxetine concentrations. J Neuropsych Clin Neurosci 5: 322–329Google Scholar
- Sunderland T, Cohen BM (1986) Blood to brain distribution of neuroleptics. Psychiatry Res 20: 299–305Google Scholar